[See: 9 Biotech Stock Funds to Buy.] But should you invest ... "Obviously there's a lot of risk, but if you look at companies like Vertex, Genentech and Amgen (AMGN) – they went public and took years to become profitable." Early in the game.
Facebook chief financial officer David Ebersman cashed in more than 900,000 shares of Facebook stock Wednesday ... Facebook in 2009 after spending years as an exec at biotech giant Genentech, helped lead Facebook through its …
Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial December 2017. Initial data is expected in late calendar 2018, and the study is expected to complete in 2021. TRX-E-002-1 (Cantrixil), is a third-generation …
The drug, whose $1,850-per-dose monthly cost is paid mostly by Medicare, has fueled Regeneron's growth and a meteoric rise in its stock price ... a cancer drug made by Roche's Genentech division, is also effective when used off …
While the two-square-mile patch of South San Francisco bustles with more than 70 biotech firms, including Genentech, Amgen and Exelixis ... Be it the size of the market, the vibrancy of the stock market or the number of VCs, California …
CVS spokeswoman Amy Lanctot said increased demand for Tamiflu in California may have led to some stores being temporarily out of stock. Other pharmacies reported ... San Francisco-based pharmaceutical company Genentech, …
Roche plays a long game, though, and has ample experience in successful hostile takeover bids for Ventana and Genentech. Don’t be surprised if Roche re-emerges if Illumina’s stock price stays low. Complicating the assessment …
SEN. DON NICKLES (R-Okla.) In March 1993, Nickles bought $3,785 worth of stock in Genentech and $3,894 worth of stock in Genetics Institute (both biotechnology firms) while Congress was considering the National Institutes of Health …